



# FINANCIAL TEAR SHEET

## Corporate Profile

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Sanfilippo disorder, Batten disease, Fanconi anemia and other rare disorders.

## Primary IR Contact

Andre'a Lucca  
 Director of Communications  
 PlasmaTech  
 Biopharmaceuticals, Inc.  
**Phone:** 212-786-6208  
**E-mail:**  
 alucca@plasmatechbio.com

## Stock Performance

### ABEO (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	<b>\$13.45</b>
Change (%)	▲ 0.10 (0.75%)
Volume	1,035,853
52 Week Low	\$4.55
Market Cap	\$629,127,207
Rolling EPS	-0.65
PE Ratio	0
Shares Outstanding	46,775,257



Data as of February 23, 2018 4:00 p.m. ET

## Recent Press Releases & Upcoming Events

February 21, 2018  
Abeona Therapeutics Announces  
Upcoming Conference Participation

There are currently no events scheduled.

February 12, 2018  
Abeona Therapeutics Receives FDA  
Orphan Drug Designation for ABO-202  
Gene Therapy Program in Infantile Batten  
Disease

February 8, 2018  
Abeona Therapeutics Reports Top-Line  
Data from Phase 1/2 Gene Therapy Trial  
in MPS IIIA

## SEC Filings

## Corporate Governance

Filing Date	Form
February 14, 2018	SC 13G/A
February 14, 2018	SC 13G/A
February 14, 2018	SC 13G/A
February 14, 2018	SC 13G/A

Data provided by Nasdaq. Minimum 15 minutes delayed.